Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.

Authors

Kerry Lynn Reynolds

Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA

Kerry Lynn Reynolds , Daniel A. Zlotoff , Meghan Mooradian , Leyre Zubiri , Paul Ridker , Tomas G. Neilan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

First Author: Daniel Olson

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.

First Author: Patrick Walsh McGarrah

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.

First Author: Amin Nassar

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Safety and efficacy of immune checkpoint inhibitors in cancer patients and pre-existing autoimmune disease: A systematic review and meta-analysis in non-small cell lung cancer.

First Author: Wint Yan Aung